JP2013511966A - 単一特異性ポリペプチド試薬 - Google Patents
単一特異性ポリペプチド試薬 Download PDFInfo
- Publication number
- JP2013511966A JP2013511966A JP2012540419A JP2012540419A JP2013511966A JP 2013511966 A JP2013511966 A JP 2013511966A JP 2012540419 A JP2012540419 A JP 2012540419A JP 2012540419 A JP2012540419 A JP 2012540419A JP 2013511966 A JP2013511966 A JP 2013511966A
- Authority
- JP
- Japan
- Prior art keywords
- igg
- cad
- seq
- fusion polypeptide
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims description 83
- 229920001184 polypeptide Polymers 0.000 title claims description 60
- 102000004196 processed proteins & peptides Human genes 0.000 title claims description 60
- 239000003153 chemical reaction reagent Substances 0.000 title claims description 19
- 239000000427 antigen Substances 0.000 claims abstract description 41
- 102000036639 antigens Human genes 0.000 claims abstract description 41
- 108091007433 antigens Proteins 0.000 claims abstract description 41
- 230000027455 binding Effects 0.000 claims description 79
- 238000009739 binding Methods 0.000 claims description 54
- 230000004927 fusion Effects 0.000 claims description 49
- 238000010276 construction Methods 0.000 claims description 36
- 241000588724 Escherichia coli Species 0.000 claims description 31
- 150000007523 nucleic acids Chemical class 0.000 claims description 30
- 235000001014 amino acid Nutrition 0.000 claims description 21
- 229940024606 amino acid Drugs 0.000 claims description 19
- 150000001413 amino acids Chemical class 0.000 claims description 19
- 108020004707 nucleic acids Proteins 0.000 claims description 18
- 102000039446 nucleic acids Human genes 0.000 claims description 18
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 17
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 16
- 108020004705 Codon Proteins 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 13
- 125000000539 amino acid group Chemical group 0.000 claims description 12
- 239000004471 Glycine Substances 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 7
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 6
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 6
- 235000004279 alanine Nutrition 0.000 claims description 6
- 238000002405 diagnostic procedure Methods 0.000 claims description 6
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims description 5
- 230000013595 glycosylation Effects 0.000 claims description 5
- 238000006206 glycosylation reaction Methods 0.000 claims description 5
- 238000012360 testing method Methods 0.000 claims description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 3
- 241000894006 Bacteria Species 0.000 claims description 3
- 238000010876 biochemical test Methods 0.000 claims description 3
- 239000012228 culture supernatant Substances 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 2
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 claims description 2
- 239000012491 analyte Substances 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 abstract description 4
- 102000025171 antigen binding proteins Human genes 0.000 abstract description 2
- 108091000831 antigen binding proteins Proteins 0.000 abstract description 2
- 108090000288 Glycoproteins Proteins 0.000 description 83
- 102000003886 Glycoproteins Human genes 0.000 description 83
- 238000006243 chemical reaction Methods 0.000 description 77
- 108090000623 proteins and genes Proteins 0.000 description 60
- 238000010790 dilution Methods 0.000 description 57
- 239000012895 dilution Substances 0.000 description 57
- 102000004169 proteins and genes Human genes 0.000 description 46
- 102000013415 peroxidase activity proteins Human genes 0.000 description 41
- 108040007629 peroxidase activity proteins Proteins 0.000 description 41
- 235000018102 proteins Nutrition 0.000 description 37
- 238000001514 detection method Methods 0.000 description 33
- 210000004027 cell Anatomy 0.000 description 29
- 238000010367 cloning Methods 0.000 description 29
- 108060003951 Immunoglobulin Proteins 0.000 description 27
- 102000018358 immunoglobulin Human genes 0.000 description 27
- 108091028043 Nucleic acid sequence Proteins 0.000 description 22
- 238000012512 characterization method Methods 0.000 description 20
- 239000012897 dilution medium Substances 0.000 description 20
- 239000012634 fragment Substances 0.000 description 19
- 238000001035 drying Methods 0.000 description 18
- 230000015572 biosynthetic process Effects 0.000 description 17
- 238000003786 synthesis reaction Methods 0.000 description 17
- 238000003018 immunoassay Methods 0.000 description 16
- 238000003556 assay Methods 0.000 description 14
- 239000000499 gel Substances 0.000 description 14
- 238000000746 purification Methods 0.000 description 13
- 238000011534 incubation Methods 0.000 description 12
- FPPNZSSZRUTDAP-UWFZAAFLSA-N carbenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)C(C(O)=O)C1=CC=CC=C1 FPPNZSSZRUTDAP-UWFZAAFLSA-N 0.000 description 11
- 229960003669 carbenicillin Drugs 0.000 description 11
- ZGSPNIOCEDOHGS-UHFFFAOYSA-L disodium [3-[2,3-di(octadeca-9,12-dienoyloxy)propoxy-oxidophosphoryl]oxy-2-hydroxypropyl] 2,3-di(octadeca-9,12-dienoyloxy)propyl phosphate Chemical compound [Na+].[Na+].CCCCCC=CCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COP([O-])(=O)OCC(O)COP([O-])(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COC(=O)CCCCCCCC=CCC=CCCCCC ZGSPNIOCEDOHGS-UHFFFAOYSA-L 0.000 description 11
- 239000002609 medium Substances 0.000 description 11
- 239000000523 sample Substances 0.000 description 11
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 10
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 10
- 229940098773 bovine serum albumin Drugs 0.000 description 10
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 10
- 239000013598 vector Substances 0.000 description 10
- 108020004414 DNA Proteins 0.000 description 9
- 230000029087 digestion Effects 0.000 description 9
- 238000005259 measurement Methods 0.000 description 9
- 108091008146 restriction endonucleases Proteins 0.000 description 9
- 125000003275 alpha amino acid group Chemical group 0.000 description 8
- 230000001771 impaired effect Effects 0.000 description 8
- 239000013612 plasmid Substances 0.000 description 8
- 241000894007 species Species 0.000 description 8
- 238000000547 structure data Methods 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 239000006142 Luria-Bertani Agar Substances 0.000 description 7
- 238000000246 agarose gel electrophoresis Methods 0.000 description 7
- 230000003429 anti-cardiolipin effect Effects 0.000 description 7
- 235000018417 cysteine Nutrition 0.000 description 7
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 7
- 229940088598 enzyme Drugs 0.000 description 7
- 238000003752 polymerase chain reaction Methods 0.000 description 7
- 230000035882 stress Effects 0.000 description 7
- 238000002965 ELISA Methods 0.000 description 6
- 230000003321 amplification Effects 0.000 description 6
- 230000008014 freezing Effects 0.000 description 6
- 238000007710 freezing Methods 0.000 description 6
- 238000003199 nucleic acid amplification method Methods 0.000 description 6
- 238000003860 storage Methods 0.000 description 6
- 230000009466 transformation Effects 0.000 description 6
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 5
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 5
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 5
- 102000016943 Muramidase Human genes 0.000 description 5
- 108010014251 Muramidase Proteins 0.000 description 5
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 5
- 238000001042 affinity chromatography Methods 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 235000009582 asparagine Nutrition 0.000 description 5
- 229960001230 asparagine Drugs 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 239000004202 carbamide Substances 0.000 description 5
- 239000012636 effector Substances 0.000 description 5
- 230000008642 heat stress Effects 0.000 description 5
- 230000006698 induction Effects 0.000 description 5
- 229960000274 lysozyme Drugs 0.000 description 5
- 235000010335 lysozyme Nutrition 0.000 description 5
- 239000004325 lysozyme Substances 0.000 description 5
- 238000013492 plasmid preparation Methods 0.000 description 5
- 229920002401 polyacrylamide Polymers 0.000 description 5
- 238000012163 sequencing technique Methods 0.000 description 5
- 238000013207 serial dilution Methods 0.000 description 5
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 5
- 238000001262 western blot Methods 0.000 description 5
- YRNWIFYIFSBPAU-UHFFFAOYSA-N 4-[4-(dimethylamino)phenyl]-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1C1=CC=C(N(C)C)C=C1 YRNWIFYIFSBPAU-UHFFFAOYSA-N 0.000 description 4
- 108091026890 Coding region Proteins 0.000 description 4
- 239000012722 SDS sample buffer Substances 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000009257 reactivity Effects 0.000 description 4
- 230000009870 specific binding Effects 0.000 description 4
- 101100006370 Arabidopsis thaliana CHX2 gene Proteins 0.000 description 3
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 3
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 3
- 101001003232 Mus musculus Immediate early response gene 2 protein Proteins 0.000 description 3
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 3
- 239000004473 Threonine Substances 0.000 description 3
- 230000000975 bioactive effect Effects 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 238000006471 dimerization reaction Methods 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 229940072221 immunoglobulins Drugs 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 150000003384 small molecules Chemical class 0.000 description 3
- 238000010257 thawing Methods 0.000 description 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 2
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 2
- -1 DNA or RNA Chemical class 0.000 description 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 2
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 2
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 102000012412 Presenilin-1 Human genes 0.000 description 2
- 108010036933 Presenilin-1 Proteins 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 101710125324 Telomere repeat-binding factor 1 Proteins 0.000 description 2
- 102000002689 Toll-like receptor Human genes 0.000 description 2
- 108020000411 Toll-like receptor Proteins 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000004255 ion exchange chromatography Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000009871 nonspecific binding Effects 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 230000000171 quenching effect Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
- 102100026445 A-kinase anchor protein 17A Human genes 0.000 description 1
- 101710137189 Amyloid-beta A4 protein Proteins 0.000 description 1
- 102100022704 Amyloid-beta precursor protein Human genes 0.000 description 1
- 101710151993 Amyloid-beta precursor protein Proteins 0.000 description 1
- 235000002198 Annona diversifolia Nutrition 0.000 description 1
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 description 1
- 101100006371 Arabidopsis thaliana CHX3 gene Proteins 0.000 description 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 101000583086 Bunodosoma granuliferum Delta-actitoxin-Bgr2b Proteins 0.000 description 1
- 108091008927 CC chemokine receptors Proteins 0.000 description 1
- 102000005674 CCR Receptors Human genes 0.000 description 1
- 241000282832 Camelidae Species 0.000 description 1
- 102000009410 Chemokine receptor Human genes 0.000 description 1
- 108050000299 Chemokine receptor Proteins 0.000 description 1
- 108700010070 Codon Usage Proteins 0.000 description 1
- 101710114790 Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 1
- 238000011238 DNA vaccination Methods 0.000 description 1
- 102100037362 Fibronectin Human genes 0.000 description 1
- 102000002090 Fibronectin type III Human genes 0.000 description 1
- 108050009401 Fibronectin type III Proteins 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 240000001973 Ficus microcarpa Species 0.000 description 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101000718019 Homo sapiens A-kinase anchor protein 17A Proteins 0.000 description 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 1
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 1
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
- 244000050403 Iris x germanica Species 0.000 description 1
- 241000282838 Lama Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108700001237 Nucleic Acid-Based Vaccines Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 102000002067 Protein Subunits Human genes 0.000 description 1
- 108010001267 Protein Subunits Proteins 0.000 description 1
- 101710083394 Protein patched Proteins 0.000 description 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 1
- 238000000333 X-ray scattering Methods 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 description 1
- 230000037429 base substitution Effects 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 229960004222 factor ix Drugs 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000012804 iterative process Methods 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000001956 neutron scattering Methods 0.000 description 1
- 229940023146 nucleic acid vaccine Drugs 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 108020001580 protein domains Proteins 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000012475 sodium chloride buffer Substances 0.000 description 1
- WYDDJDOHZRIHDA-UHFFFAOYSA-M sodium chloride trihydrochloride Chemical compound [Na+].Cl.Cl.Cl.[Cl-] WYDDJDOHZRIHDA-UHFFFAOYSA-M 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/528—CH4 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102009047243A DE102009047243A1 (de) | 2009-11-27 | 2009-11-27 | Monospezifische Polypeptidreagenzien |
| DE102009047243.6 | 2009-11-27 | ||
| PCT/EP2010/068134 WO2011064257A2 (de) | 2009-11-27 | 2010-11-24 | Monospezifische polypeptidreagenzien |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013511966A true JP2013511966A (ja) | 2013-04-11 |
| JP2013511966A5 JP2013511966A5 (enExample) | 2014-01-09 |
Family
ID=43589669
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012540419A Pending JP2013511966A (ja) | 2009-11-27 | 2010-11-24 | 単一特異性ポリペプチド試薬 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US9163079B2 (enExample) |
| EP (1) | EP2504359B1 (enExample) |
| JP (1) | JP2013511966A (enExample) |
| AU (1) | AU2010323144B2 (enExample) |
| CA (1) | CA2782016C (enExample) |
| DE (1) | DE102009047243A1 (enExample) |
| DK (1) | DK2504359T3 (enExample) |
| WO (1) | WO2011064257A2 (enExample) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2022528030A (ja) * | 2019-01-07 | 2022-06-08 | トーマス・ジェファーソン・ユニバーシティ | 多機能性融合タンパク質及びその使用 |
| US12497439B2 (en) | 2020-01-07 | 2025-12-16 | Thomas Jefferson University | Multi-functional fusion proteins and uses thereof |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2032166T3 (pl) | 2006-06-13 | 2013-09-30 | Oncomed Pharm Inc | Kompozycje i sposoby diagnozowania i leczenia nowotworów |
| JP5618544B2 (ja) | 2007-01-24 | 2014-11-05 | オンコメッドファーマシューティカルズ インコーポレイテッド | 癌の診断および処置のための組成物および方法 |
| CN102316897B (zh) | 2008-07-08 | 2014-11-05 | 昂考梅德药品有限公司 | Notch结合剂和拮抗剂及其应用方法 |
| DE102009047243A1 (de) * | 2009-11-27 | 2011-06-01 | Orgentec Diagnostika Gmbh | Monospezifische Polypeptidreagenzien |
| WO2013156054A1 (en) | 2012-04-16 | 2013-10-24 | Universität Stuttgart | The igm and ige heavy chain domain 2 as covalently linked homodimerization modules for the generation of fusion proteins with dual specificity |
| US20170023576A1 (en) * | 2014-04-04 | 2017-01-26 | Oncomed Pharmaceuticals, Inc. | Notch3 antibodies and uses thereof |
| CN109641949B (zh) * | 2016-08-26 | 2023-09-15 | 赛诺菲 | 促进选择性轻链配对的多特异性抗体 |
| US11124562B2 (en) | 2016-10-28 | 2021-09-21 | Washington University | Anti-ApoE antibodies |
| EP4582442A3 (en) | 2019-06-24 | 2025-10-29 | Universität Stuttgart | Tnfr2 agonists with improved stability |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2000516452A (ja) * | 1996-07-16 | 2000-12-12 | プリュックテュン，アンドレアス | 可溶性が増大した免疫グロブリンスーパーファミリードメインおよびフラグメント |
| JP2003501096A (ja) * | 1999-06-07 | 2003-01-14 | ネオルクス コーポレイション | ストレプトアビジン発現性遺伝子融合およびその使用方法 |
| WO2005017148A1 (en) * | 2003-07-26 | 2005-02-24 | Trubion Pharmaceuticals, Inc. | Binding constructs and methods for use thereof |
| WO2008131242A1 (en) * | 2007-04-18 | 2008-10-30 | Zymogenetics, Inc. | Single chain fc, methods of making and methods of treatment |
| JP2009544300A (ja) * | 2006-07-25 | 2009-12-17 | ユセベ ファルマ ソシエテ アノニム | 単鎖Ｆｃポリペプチド |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994009817A1 (en) | 1992-11-04 | 1994-05-11 | City Of Hope | Novel antibody construct |
| US6015662A (en) | 1996-01-23 | 2000-01-18 | Abbott Laboratories | Reagents for use as calibrators and controls |
| EP0985039B1 (en) | 1997-06-12 | 2008-02-20 | Novartis International Pharmaceutical Ltd. | Artificial antibody polypeptides |
| US6151296A (en) | 1997-06-19 | 2000-11-21 | Qualcomm Incorporated | Bit interleaving for orthogonal frequency division multiplexing in the transmission of digital signals |
| DE10001372A1 (de) | 2000-01-14 | 2001-08-02 | Deutsches Krebsforsch | Anti-CD3-Einzelketten-Antikörper mit humanem Cmu3- und Cmu4- Domänen |
| US8420353B2 (en) | 2002-03-22 | 2013-04-16 | Aprogen, Inc. | Humanized antibody and process for preparing same |
| WO2006117782A2 (en) * | 2005-05-04 | 2006-11-09 | Quark Pharmaceuticals, Inc. | Recombinant antibodies against cd55 and cd59 and uses thereof |
| CN101228188A (zh) * | 2005-06-21 | 2008-07-23 | 佐马技术有限公司 | IL-1β结合抗体及其片段 |
| EP1757622B1 (en) * | 2005-08-26 | 2009-12-23 | PLS Design GmbH | Bivalent IgY antibody constructs for diagnostic and therapeutic applications |
| JP5102772B2 (ja) * | 2005-11-29 | 2012-12-19 | ザ・ユニバーシティ・オブ・シドニー | デミボディ：二量体化活性化治療剤 |
| EP1954187A1 (en) | 2005-12-01 | 2008-08-13 | Atcor Medical Pty Ltd | A method of estimating pulse wave velocity |
| WO2007109321A2 (en) | 2006-03-20 | 2007-09-27 | The Regents Of The University Of California | Engineered anti-prostate stem cell antigen (psca) antibodies for cancer targeting |
| EP2139800A1 (en) * | 2007-04-20 | 2010-01-06 | Invista Technologies S.à.r.l. | Compact continuous over end take-off (oeto) creel with tension control |
| WO2008145137A2 (en) * | 2007-05-31 | 2008-12-04 | Genmab A/S | Recombinant non glycosylated monovalent half-antibodies obtained by molecular engineering |
| EP2116555A1 (en) * | 2008-05-08 | 2009-11-11 | Bayer Schering Pharma Aktiengesellschaft | Use of a radioactively labelled molecule specifically binding to ED-B fibronectin in a method of treatment of Hodgkin lymphoma |
| DE102009047243A1 (de) * | 2009-11-27 | 2011-06-01 | Orgentec Diagnostika Gmbh | Monospezifische Polypeptidreagenzien |
-
2009
- 2009-11-27 DE DE102009047243A patent/DE102009047243A1/de not_active Withdrawn
-
2010
- 2010-11-24 DK DK10798744.8T patent/DK2504359T3/da active
- 2010-11-24 US US13/512,206 patent/US9163079B2/en active Active
- 2010-11-24 WO PCT/EP2010/068134 patent/WO2011064257A2/de not_active Ceased
- 2010-11-24 JP JP2012540419A patent/JP2013511966A/ja active Pending
- 2010-11-24 AU AU2010323144A patent/AU2010323144B2/en not_active Ceased
- 2010-11-24 CA CA2782016A patent/CA2782016C/en active Active
- 2010-11-24 EP EP10798744.8A patent/EP2504359B1/de active Active
-
2015
- 2015-09-09 US US14/848,636 patent/US9815891B2/en active Active
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2000516452A (ja) * | 1996-07-16 | 2000-12-12 | プリュックテュン，アンドレアス | 可溶性が増大した免疫グロブリンスーパーファミリードメインおよびフラグメント |
| JP2003501096A (ja) * | 1999-06-07 | 2003-01-14 | ネオルクス コーポレイション | ストレプトアビジン発現性遺伝子融合およびその使用方法 |
| WO2005017148A1 (en) * | 2003-07-26 | 2005-02-24 | Trubion Pharmaceuticals, Inc. | Binding constructs and methods for use thereof |
| JP2007528194A (ja) * | 2003-07-26 | 2007-10-11 | トルビオン・ファーマシューティカルズ・インコーポレイテッド | 結合構築体およびその使用方法 |
| JP2009544300A (ja) * | 2006-07-25 | 2009-12-17 | ユセベ ファルマ ソシエテ アノニム | 単鎖Ｆｃポリペプチド |
| WO2008131242A1 (en) * | 2007-04-18 | 2008-10-30 | Zymogenetics, Inc. | Single chain fc, methods of making and methods of treatment |
Non-Patent Citations (12)
| Title |
|---|
| ANDERSEN, C.B. ET AL., PROTEIN SCI., vol. 19, JPN6016017609, 15 December 2009 (2009-12-15), pages 279 - 290, ISSN: 0003315611 * |
| ARNDT, K.M. ET AL., BIOCHEMISTRY, vol. 37, JPN6015039471, 1998, pages 12918 - 12926, ISSN: 0003166010 * |
| DESPLANCQ, D. ET AL., PROTEIN ENG., vol. 7, no. 8, JPN6016017600, 1994, pages 1027 - 1033, ISSN: 0003315607 * |
| DIMITROV, D.S., MABS, vol. 1, no. 1, JPN6014053642, 1 January 2009 (2009-01-01), pages 26 - 28, ISSN: 0002968150 * |
| FAST, J.L. ET AL., BIOCHEMISTRY, vol. 48, JPN6016017605, 11 September 2009 (2009-09-11), pages 11724 - 11736, ISSN: 0003315608 * |
| HU, S. ET AL., CANCER RES., vol. 56, JPN6016017603, 1996, pages 3055 - 3061, ISSN: 0003315609 * |
| JUNG, S. AND PLUCKTHUN, A., PROTEIN ENG., vol. 10, no. 8, JPN6016017607, 1997, pages 959 - 966, ISSN: 0003315610 * |
| LI, E. ET AL., PROTEIN ENG., vol. 10, no. 6, JPN6014053644, 1997, pages 731 - 736, ISSN: 0002968151 * |
| OLAFSEN, T. ET AL., PROTEIN ENG. DES. SEL., vol. 17, no. 4, JPN6014053649, 2004, pages 315 - 323, ISSN: 0002968154 * |
| SHAO, C. AND ZHANG, J., CELL. MOL. IMMUNOL., vol. 5, no. 4, JPN6014053645, 2008, pages 299 - 306, ISSN: 0002968152 * |
| TURNER, D.J. ET AL., J. IMMUNOL. METHODS, vol. 205, JPN6015039473, 1997, pages 43 - 54, ISSN: 0003166011 * |
| WU, A.M. ET AL., PROTEIN ENG., vol. 14, no. 12, JPN6014053647, 2001, pages 1025 - 1033, ISSN: 0002968153 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2022528030A (ja) * | 2019-01-07 | 2022-06-08 | トーマス・ジェファーソン・ユニバーシティ | 多機能性融合タンパク質及びその使用 |
| JP7587505B2 (ja) | 2019-01-07 | 2024-11-20 | トーマス・ジェファーソン・ユニバーシティ | 多機能性融合タンパク質及びその使用 |
| US12497439B2 (en) | 2020-01-07 | 2025-12-16 | Thomas Jefferson University | Multi-functional fusion proteins and uses thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| US9815891B2 (en) | 2017-11-14 |
| AU2010323144B2 (en) | 2013-11-07 |
| WO2011064257A2 (de) | 2011-06-03 |
| EP2504359B1 (de) | 2016-03-23 |
| CA2782016A1 (en) | 2011-06-03 |
| EP2504359A2 (de) | 2012-10-03 |
| US20160046703A1 (en) | 2016-02-18 |
| WO2011064257A3 (de) | 2011-08-11 |
| US9163079B2 (en) | 2015-10-20 |
| DE102009047243A1 (de) | 2011-06-01 |
| DK2504359T3 (da) | 2016-07-25 |
| AU2010323144A1 (en) | 2012-07-12 |
| CA2782016C (en) | 2020-01-07 |
| US20120276099A1 (en) | 2012-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9815891B2 (en) | Monospecific polypeptide reagents | |
| JP6165713B2 (ja) | インスリン様増殖因子１に特異的に結合する抗体 | |
| CN110256569B (zh) | 具有交换结合区取向的双重可变区抗体样结合蛋白 | |
| CN116897166A (zh) | 抗GPRC5DxBCMAxCD3三特异性抗体及其用途 | |
| KR102651965B1 (ko) | 신규 항 cd3 항체 | |
| KR20190134614A (ko) | B7-h3 항체, 이의 항원-결합 단편 및 이의 의학적 용도 | |
| JP2023509212A (ja) | 新型ポリペプチド複合物 | |
| WO2021047559A1 (zh) | 一种断裂型内含肽、使用其的重组多肽的制备方法 | |
| US11505614B2 (en) | Antibodies binding to soluble BCMA | |
| TWI789399B (zh) | 不對稱異二聚fc-scfv融合抗globo h及抗cd3雙特異性抗體及其於癌症治療上之用途 | |
| CN109336973B (zh) | 抗转铁蛋白抗体及其用途 | |
| US20240199726A1 (en) | Antibodies targeting talaromyces marneffei mp1p protein and methods of use thereof | |
| US20220235139A1 (en) | Anti-csf-ir antibody | |
| US20230324388A1 (en) | Antibody for porcine reproductive and respiratory syndrome virus and uses thereof | |
| RU2737466C1 (ru) | Гуманизированное нейтрализующее антитело к интерферону-бета человека | |
| EP4194054A1 (en) | Camelid antibodies for use in therapy and diagnosis | |
| CN120718146A (zh) | 抗人TNF-β的单克隆抗体及其应用 | |
| WO2024255756A1 (zh) | 基于共同轻链产生双特异性抗体的方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20131113 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20131113 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20141222 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20150323 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150416 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20151005 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160104 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20160516 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20160601 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20160601 |